FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549412239> ?p ?o ?g. }

• W2549412239 abstract "Abstract Abstract 99 Whole genome sequencing with next generation technologies represents a new, unbiased approach for discovering somatic variations in cancer genomes. Our group recently reported the DNA sequence and analysis of the genomes of two patients with normal karyotype acute myeloid leukemia (AML). Improvements in next generation sequencing technologies (principally, paired-end sequencing) led us to reevaluate the first case (Ley et al, Nature 456:66–72, 2008) with deeper sequence coverage. We discovered a novel frameshift mutation in DNMT3A, one of the three genes in humans (DNMT1, DNMT3A, and DNMT3B) that encodes a DNA methyltransferase that catalyzes the addition of methyl groups to cytosine within CpG dinucleotides. We then sequenced all the coding exons of this gene in 280 additional de novo cases of AML to define recurring mutations. 62/281 de novo AML cases (22%) had mutations with translational effects in the DNMT3A gene. 18 different missense mutations were identified, the most common of which was at amino acid R882 (37 cases). Frameshifts (n=6), nonsense mutations (n=6), splice site mutations (n=3), and a 1.5 Mbp deletion that included the DNMT3A gene were also identified. DNMT3A mutations were highly enriched in cases with intermediate risk cytogenetics (56/166=33.7%; p<0.0001) and were not found in any cases with favorable cytogenetics (0/79; p<0.0001). Genomic 5-methylcytosine content, the general pattern of CpG island methylation, and gene expression patterns were essentially unaltered in genomes with DNMT3A mutations. The median overall survival of all AML patients with DNMT3A mutations was strikingly reduced, regardless of whether the mutation was at R882 or any other site (12.3 vs. 41.1 months, p<0.0001, Figure A). Patients with a FLT3 ITD mutation and no DNMT3A mutation (n=39) had a median survival of 33.5 months, but patients with a FLT3 ITD mutation and any DNMT3A mutation (n=18) had a median survival of 7.7 months (p=0.003, Figure B). Finally, DNMT3A mutation status independently predicted poor outcomes in a Cox Proportional Hazards analysis. In sum, DNMT3A mutations are highly recurrent in de novo AML cases with intermediate risk cytogenetics, and are independently associated with poor survival. These mutations may be valuable for identifying patients who need early intensification of therapy (allogeneic stem cell transplantation and/or innovative early phase clinical trials in first remission or consolidation). Disclosures: Westervelt: Novartis: Honoraria; Celgene: Honoraria, Speakers Bureau. DiPersio:Genzyme: Honoraria." @default.
• W2549412239 created "2016-11-30" @default.
• W2549412239 creator A5006502306 @default.
• W2549412239 creator A5006577168 @default.
• W2549412239 creator A5007830810 @default.
• W2549412239 creator A5009112568 @default.
• W2549412239 creator A5013444791 @default.
• W2549412239 creator A5013993509 @default.
• W2549412239 creator A5014714324 @default.
• W2549412239 creator A5018151522 @default.
• W2549412239 creator A5021913825 @default.
• W2549412239 creator A5022808238 @default.
• W2549412239 creator A5030586623 @default.
• W2549412239 creator A5033142370 @default.
• W2549412239 creator A5035432960 @default.
• W2549412239 creator A5036363023 @default.
• W2549412239 creator A5038288423 @default.
• W2549412239 creator A5041014552 @default.
• W2549412239 creator A5041520404 @default.
• W2549412239 creator A5041753570 @default.
• W2549412239 creator A5042552121 @default.
• W2549412239 creator A5044189301 @default.
• W2549412239 creator A5046034812 @default.
• W2549412239 creator A5047326660 @default.
• W2549412239 creator A5049284725 @default.
• W2549412239 creator A5052629830 @default.
• W2549412239 creator A5054198772 @default.
• W2549412239 creator A5054642128 @default.
• W2549412239 creator A5056864458 @default.
• W2549412239 creator A5056921013 @default.
• W2549412239 creator A5057508602 @default.
• W2549412239 creator A5057644497 @default.
• W2549412239 creator A5061026009 @default.
• W2549412239 creator A5064410148 @default.
• W2549412239 creator A5064617740 @default.
• W2549412239 creator A5065066309 @default.
• W2549412239 creator A5068833334 @default.
• W2549412239 creator A5069161297 @default.
• W2549412239 creator A5074942308 @default.
• W2549412239 creator A5076523265 @default.
• W2549412239 creator A5076598094 @default.
• W2549412239 creator A5077134737 @default.
• W2549412239 creator A5078124570 @default.
• W2549412239 creator A5081851296 @default.
• W2549412239 creator A5082251778 @default.
• W2549412239 creator A5084251059 @default.
• W2549412239 creator A5084949368 @default.
• W2549412239 creator A5088266338 @default.
• W2549412239 creator A5089826284 @default.
• W2549412239 creator A5091758093 @default.
• W2549412239 date "2010-11-19" @default.
• W2549412239 modified "2023-10-08" @default.
• W2549412239 title "Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes" @default.
• W2549412239 doi "https://doi.org/10.1182/blood.v116.21.99.99" @default.
• W2549412239 hasPublicationYear "2010" @default.
• W2549412239 type Work @default.
• W2549412239 sameAs 2549412239 @default.
• W2549412239 citedByCount "0" @default.
• W2549412239 crossrefType "journal-article" @default.
• W2549412239 hasAuthorship W2549412239A5006502306 @default.
• W2549412239 hasAuthorship W2549412239A5006577168 @default.
• W2549412239 hasAuthorship W2549412239A5007830810 @default.
• W2549412239 hasAuthorship W2549412239A5009112568 @default.
• W2549412239 hasAuthorship W2549412239A5013444791 @default.
• W2549412239 hasAuthorship W2549412239A5013993509 @default.
• W2549412239 hasAuthorship W2549412239A5014714324 @default.
• W2549412239 hasAuthorship W2549412239A5018151522 @default.
• W2549412239 hasAuthorship W2549412239A5021913825 @default.
• W2549412239 hasAuthorship W2549412239A5022808238 @default.
• W2549412239 hasAuthorship W2549412239A5030586623 @default.
• W2549412239 hasAuthorship W2549412239A5033142370 @default.
• W2549412239 hasAuthorship W2549412239A5035432960 @default.
• W2549412239 hasAuthorship W2549412239A5036363023 @default.
• W2549412239 hasAuthorship W2549412239A5038288423 @default.
• W2549412239 hasAuthorship W2549412239A5041014552 @default.
• W2549412239 hasAuthorship W2549412239A5041520404 @default.
• W2549412239 hasAuthorship W2549412239A5041753570 @default.
• W2549412239 hasAuthorship W2549412239A5042552121 @default.
• W2549412239 hasAuthorship W2549412239A5044189301 @default.
• W2549412239 hasAuthorship W2549412239A5046034812 @default.
• W2549412239 hasAuthorship W2549412239A5047326660 @default.
• W2549412239 hasAuthorship W2549412239A5049284725 @default.
• W2549412239 hasAuthorship W2549412239A5052629830 @default.
• W2549412239 hasAuthorship W2549412239A5054198772 @default.
• W2549412239 hasAuthorship W2549412239A5054642128 @default.
• W2549412239 hasAuthorship W2549412239A5056864458 @default.
• W2549412239 hasAuthorship W2549412239A5056921013 @default.
• W2549412239 hasAuthorship W2549412239A5057508602 @default.
• W2549412239 hasAuthorship W2549412239A5057644497 @default.
• W2549412239 hasAuthorship W2549412239A5061026009 @default.
• W2549412239 hasAuthorship W2549412239A5064410148 @default.
• W2549412239 hasAuthorship W2549412239A5064617740 @default.
• W2549412239 hasAuthorship W2549412239A5065066309 @default.
• W2549412239 hasAuthorship W2549412239A5068833334 @default.
• W2549412239 hasAuthorship W2549412239A5069161297 @default.
• W2549412239 hasAuthorship W2549412239A5074942308 @default.
• W2549412239 hasAuthorship W2549412239A5076523265 @default.
• W2549412239 hasAuthorship W2549412239A5076598094 @default.
• W2549412239 hasAuthorship W2549412239A5077134737 @default.
• W2549412239 hasAuthorship W2549412239A5078124570 @default.

• next